Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.58 |
| ▸ | TLR2 | O60603 | 1/20 | 0.46 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13671200 | 0.85 | MEN1 (0.42) | SLC6A3SLC6A4SLC6A2TLR2TLR1 | |
| SCHEMBL13041171 | 0.85 | MEN1 (0.42) | SLC6A3SLC6A4SLC6A2TLR2TLR1 | |
| SCHEMBL13041181 | 0.82 | PDE5A (0.42) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL13525560 | 0.80 | SLC6A2 (0.76) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL31703378 | 0.77 | SLC6A3 (0.60) | SLC6A3SLC6A4SLC6A2TLR2TLR1 | |
| SCHEMBL14065595 | 0.76 | SLC6A2 (0.43) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL14065597 | 0.76 | SLC6A2 (0.43) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL14065593 | 0.75 | MAPT (0.54) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL12592383 | 0.75 | SLC6A3 (0.53) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL14065598 | 0.75 | MAPT (0.54) | SLC6A3SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354545-B2 | 3,4-substituted pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease | Merck, Sharp & Dohme, Corp. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20100280009-A1 | 3,4-SUBSTITUTED PYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LLC | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280009-A1 | 3,4-SUBSTITUTED PYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BACE1, BACE2, PSEN1 | SLC6A3 3284/4885SLC6A4 4237/4885SLC6A2 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.